-
公开(公告)号：US20220073636A1
公开(公告)日：2022-03-10
申请号：US17522008
申请日：2021-11-09
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. NADLER , James K. TAMURA , Laura PRICE , Robert P. REHFUSS , Suzanne J. SUCHARD , Anish SURI , James William BRYSON , Aaron YAMNIUK , Steven GRANT , Olga IGNATOVICH , Philip DREW
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/46 , C07K16/18
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US20200148779A1
公开(公告)日：2020-05-14
申请号：US16495994
申请日：2018-05-24
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Suzanne J. SUCHARD
IPC: C07K16/28
Abstract: Modified IgG1 Fc domains having reduced binding to Fc-gamma-receptors are provided. Further provided are fusion polypeptides comprising a modified IgG1 Fc domain. An antibody polypeptide that specifically binds a human CD40 is provided, wherein the antibody polypeptides are fusions of a domain antibody (dAb) comprising a single VH domain and an Fc domain. The antibody polypeptides do not exhibit CD40 agonist activity, do not substantially activate immature dendritic cells, and have improved biophysical properties.
-
公开(公告)号：US20160075790A1
公开(公告)日：2016-03-17
申请号：US14950949
申请日：2015-11-24
Applicant: Domantis Limited , Bristol-Myers Squibb Company
Inventor： Steven G. NADLER , James K. TAMURA , Laura PRICE , Robert P. REHFUSS , Suzanne J. SUCHARD , Anish SURI , James William BRYSON , Aaron YAMNIUK , Steven GRANT , Olga IGNATOVICH , Philip DREW
IPC: C07K16/28 , A61K45/06 , C07K16/18 , C07K16/46 , A61K39/395
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US20240124597A1
公开(公告)日：2024-04-18
申请号：US18453691
申请日：2023-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20210054090A1
公开(公告)日：2021-02-25
申请号：US17080626
申请日：2020-10-26
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
Patent Agency Ranking
公开(公告)号：US20190100595A1
公开(公告)日：2019-04-04
申请号：US16218077
申请日：2018-12-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. NADLER , James K. TAMURA , Laura PRICE , Robert P. REHFUSS , Suzanne J. SUCHARD , Anish SURI , James William BRYSON , Aaron YAMNIUK , Steven GRANT , Olga IGNATOVICH , Philip DREW
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
公开(公告)号：US20220177596A1
公开(公告)日：2022-06-09
申请号：US17561529
申请日：2021-12-23
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Suzanne J. SUCHARD
IPC: C07K16/28 , A61K39/395
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20220153856A1
公开(公告)日：2022-05-19
申请号：US17588518
申请日：2022-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20170015754A1
公开(公告)日：2017-01-19
申请号：US15259828
申请日：2016-09-08
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Anish SURI , Steven SHERIFF , Suzanne SUCHARD , Aaron YAMNIUK , Stanley KRYSTEK , James TAMURA , James BRYSON , Steven GRANT , Philip DREW
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/18
Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
Abstract translation: 提供特异性结合人CD40的新表位的抗体多肽。 抗体多肽不表现出CD40激动剂活性。 抗体多肽可用于治疗涉及CD40活化的疾病，例如自身免疫性疾病。 抗体多肽可以是包含单个VL或VH结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）的双特异性试剂来增加。
-
公开(公告)号：US20130095109A1
公开(公告)日：2013-04-18
申请号：US13650493
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. NADLER , James K. TAMURA , Laura PRICE , Robert P. REHFUSS , Suzanne J. SUCHARD , Anish SURI , James William BRYSON , Aaron YAMNIUK , Steven GRANT , Olga IGNATOVICH , Philip DREW
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/46
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.024 seconds)
